Nanobiotix (NBTX) Revenue & Revenue Breakdown
Nanobiotix Revenue Highlights
Latest Revenue (Y)
$30.06M
Latest Revenue (Q)
$30.06M
Main Segment (Y)
Services
Main Geography (Y)
Other Sales
Nanobiotix Revenue by Period
Nanobiotix Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $30.06M | 529.36% |
2022-12-31 | $4.78M | 47660.00% |
2021-12-31 | $10.00K | -80.00% |
2020-12-31 | $50.00K | -26.47% |
2019-12-31 | $68.00K | -41.38% |
2018-12-31 | $116.00K | -53.96% |
2017-12-31 | $251.97K | -83.83% |
2016-12-31 | $1.56M | 486.76% |
2015-12-31 | $265.54K | -72.55% |
2014-12-31 | $967.50K | 423.15% |
2013-12-31 | $184.94K | 149.40% |
2012-12-31 | $74.15K | -94.55% |
2011-12-31 | $1.36M | - |
Nanobiotix Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2023-12-31 | $30.06M | 82.64% |
2023-09-30 | $16.46M | 899.54% |
2023-06-30 | $1.65M | - |
2023-03-31 | $1.65M | -4.47% |
2022-12-31 | $1.72M | - |
2022-09-30 | $1.72M | 159.37% |
2022-06-30 | $664.50K | -6.34% |
2020-06-30 | $709.50K | - |
Nanobiotix Revenue Breakdown
Nanobiotix Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 21 | Dec 20 |
---|---|---|---|
Services | $29.75M | $5.00K | $50.00K |
Other Sales | - | $5.00K | - |
Quarterly Revenue by Product
Product/Service | Jun 21 |
---|---|
Other Sales | $5.00K |
Services | $5.00K |
Nanobiotix Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 21 | Dec 20 |
---|---|---|
Other Sales | $5.00K | - |
Services | $5.00K | $50.00K |
Quarterly Revenue by Country
Country | Jun 21 |
---|---|
Services | $5.00K |
Other Sales | $5.00K |
Nanobiotix Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
WVE | Wave Life Sciences | $113.31M | $19.69M |
NBTX | Nanobiotix | $30.06M | $30.06M |
VECT | VectivBio | $27.34M | $676.00K |
TCRX | TScan Therapeutics | $21.05M | - |
CUE | Cue Biopharma | $5.49M | $1.72M |
TFFP | TFF Pharmaceuticals | $733.87K | $650.22K |
PALI | Palisade Bio | $250.00K | - |
AVRO | AVROBIO | - | - |
CNSP | CNS Pharmaceuticals | - | - |
CYTO | Altamira Therapeutics | - | $52.73K |
ZURA | Zura Bio | - | - |
INAB | IN8bio | - | - |
CGTX | Cognition Therapeutics | - | - |
ANNX | Annexon | - | - |
DRMA | Dermata Therapeutics | - | - |
ZVSA | ZyVersa Therapeutics | - | - |
IMMX | Immix Biopharma | - | - |
HEPA | Hepion Pharmaceuticals | - | - |
ENVB | Enveric Biosciences | - | - |
EFTR | eFFECTOR Therapeutics | - | - |
NBTX Revenue FAQ
What is Nanobiotix’s yearly revenue?
Nanobiotix's yearly revenue for 2023 was $30.06M, representing an increase of 529.36% compared to 2022. The company's yearly revenue for 2022 was $4.78M, representing an increase of 47660.00% compared to 2021. NBTX's yearly revenue for 2021 was $10K, representing a decrease of -80.00% compared to 2020.
What is Nanobiotix’s quarterly revenue?
Nanobiotix's quarterly revenue for Q4 2023 was $30.06M, a 82.64% increase from the previous quarter (Q3 2023), and a 1644.01% increase year-over-year (Q4 2022). The company's quarterly revenue for Q3 2023 was $16.46M, a 899.54% increase from the previous quarter (Q2 2023), and a 854.89% increase year-over-year (Q3 2022). NBTX's quarterly revenue for Q2 2023 was $1.65M, a 0% increase from the previous quarter (Q1 2023), and a 147.78% increase year-over-year (Q2 2022).
What is Nanobiotix’s revenue growth rate?
Nanobiotix's revenue growth rate for the last 3 years (2021-2023) was 300480.00%, and for the last 5 years (2019-2023) was 44102.94%.
What are Nanobiotix’s revenue streams?
Nanobiotix's revenue streams in c 23 are Services
What is Nanobiotix’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Nanobiotix was Services. This segment made a revenue of $29.75M, representing 100.00% of the company's total revenue.